The research of optimizing antiplatelet therapy of coronary atherosclerotic heart disease

Dual antiplatelet therapy with aspirin and clopidogrel is the standard of care for patients with acute coronary syndrome(ACS) and those who undergoing percutaneous coronary intervention(PCI).However,clopidogrel has drawbacks which leads to find the ideal antiplatelet therapy.The higher-than-standard clopidogrel dosing regimens provided greater inhibition of platelet function and improved clinical outcomes with a small but significant increase in major bleeding.Newer,more potent antiplatelet agents such as prasugrel and ticagrelor results in the best short-and long-term outcomes for patients with ACS or those undergoing PCI.The related research advances are reviewed in this paper.